Factors associated with improved survival among young adult melanoma patients despite a greater incidence of sentinel lymph node metastasis.

Chagpar, Ryaz B; Ross, Merrick I; Reintgen, Douglas S; Edwards, Michael J; Scoggins, Charles R; Martin, Robert C G; Noyes, R Dirk; Goydos, James S; Beitsch, Peter D; Urist, Marshall M; Ariyan, Stephan; Davidson, B Scott; Sussman, Jeffrey J; McMasters, Kelly M

People

Help

CiteReady is an online personal knowledge management tool. Click to find out more!

James's Profile

James's Publications

Publicly Shared Collections

Shared by James Goydos

My Publications

Updated in 8/12/2020 12:04:44 PM

Viewed: 146 times

(Journal Article)

The Journal of surgical research 143 (1): 164-8 (2007)

Factors associated with improved survival among young adult melanoma patients despite a greater incidence of sentinel lymph node metastasis.

Ryaz B Chagpar , Merrick I Ross , Douglas S Reintgen , Michael J Edwards , Charles R Scoggins , Robert C G Martin , R Dirk Noyes , James S Goydos , Peter D Beitsch , Marshall M Urist , Stephan Ariyan , B Scott Davidson , Jeffrey J Sussman , Kelly M McMasters

ABSTRACT
We sought to evaluate the factors that affect sentinel lymph node (SLN) metastasis and survival among young melanoma patients (< or =30 y).The Sunbelt Melanoma Trial is a multi-institutional prospective randomized trial of patients aged 18 to 70 y. Statistical analyses were performed to determine if patients < or =30 y of age had a significantly different outcome in terms of SLN metastasis, disease-free survival (DFS), and overall survival (OS) compared to older patients.The median age of the 3031 patients in this study was 50 y (range 18 to 77 y); the 315 patients (10.4%) < or =30 y old were compared with those >30 y old. Of the 1944 patients with follow-up, the median follow-up was 48 mo. On univariate analysis, younger patients were more often female (54.7% versus 40.9%, P < 0.0005), with tumors <4 mm thick (94.9% versus 89.4%, P = 0.001) without ulceration (80.3% versus 70.9%, P < 0.0005) or evidence of regression (93.8% versus 87.8%, P = 0.003), and were less likely to have lentigo maligna (0.0% versus 2.6%) or acral lentiginous (0.4% versus 3.1%, P < 0.0005) subtype. Patient age < or =30 was associated with SLN metastasis on univariate (24.6% versus 19.7%, P = 0.05) and multivariate (OR = 1.77, 95% CI = 1.26-2.49, P = 0.001) analyses. With a median follow-up of 48 mo, younger patients had a significantly improved 5-y DFS (86.2% versus 79.1%, P = 0.036) and OS (89.9% versus 80.1%, P = 0.010). On multivariable Cox regression analysis, however, age group was not a significant independent prognostic factor affecting DFS or OS.Despite a higher rate of SLN metastasis, patients < or =30 y old do not have a worse survival attributable to a more favorable clinicopathologic profile.

DOI: 10.1016/j.jss.2007.04.004

ISSN: 0022-4804

Report this

Community
People

Position:	Professor
About me:	James Goydos, MD is widely recognized as an expert in melanoma research & surgical oncology. In his over 20 years of experience as a surgeon, he has conducted research that has translated into patient care, clinical trials, & cutting-edge treatment. His research and clinical trials have recorded growth arrest in melanoma cells, transforming the area of cancer genomics. Goydos has decades of experience as a Professor of Surgery and researcher at UMDNJ Robert Wood Johnson Medical School. He is an advocate for patient privacy and is recognized for leadership in patient care by the Cancer Institute of New Jersey and MRF. By 2020, his work in melanoma & innovative trials have led him to record numerous awards by Castle Connolly. He has helped individuals to better understand the mechanics of melanoma, the invasion of the dermis, and to see that it is not always a death sentence.
ORCID: